Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Agouron Pharmaceuticals
• Treatments: Lamivudine; Lamivudine, zidovudine drug combination; Nelfinavir; Zidovudine

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are HIV-positive.

• Are at least 13 years old (consent of parent or guardian required if under 18).

• Have a viral load of at least 10,000 copies/ml.

• Have a CD4 count of at least 250 cells/mm3.

• Have never taken any anti-HIV drugs before.